PRO DEX Inc key statistics and ratios
In fiscal 2026, PRO DEX Inc had return on equity of 32.4%, an operating margin of 16.8%, debt equal to 45.6% of equity and a current ratio of 4.10. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 42.1% | 31.4% | 30.3% | 27.4% | 27.7% | 24.4% | 32.7% | 35.4% | 36.0% | 37.7% | 35.7% | 31.2% | 27.7% | 27.0% | 29.3% | 31.4% | 32.5% |
| Operating margin | 14.5% | −7.9% | −15.5% | −7.5% | −6.7% | 4.0% | 12.5% | 10.6% | 18.4% | 20.3% | 11.9% | 12.2% | 12.5% | 13.3% | 16.1% | 16.8% | 16.8% |
| Net margin | 11.0% | −5.1% | −14.6% | −4.5% | −2.7% | 4.1% | 23.2% | 7.2% | 15.3% | 17.5% | 16.2% | 10.9% | 15.3% | 4.0% | 13.5% | 17.6% | 15.1% |
| Free-cash-flow margin | 10.9% | −1.7% | −11.1% | −3.5% | −7.6% | 0.8% | 12.0% | 9.7% | 7.1% | 12.7% | −10.1% | −5.9% | — | — | −4.4% | 8.7% | 13.4% |
| Return on equity | 25.6% | −8.8% | −20.4% | −5.7% | −4.1% | 9.5% | 45.0% | 10.5% | 24.2% | 33.9% | 30.7% | 19.6% | 24.8% | 6.8% | 26.6% | 32.4% | 24.8% |
| Return on assets | 17.0% | −6.2% | −15.2% | −4.4% | −3.0% | 6.9% | 37.0% | 8.9% | 18.3% | 21.6% | 17.3% | 10.2% | 14.0% | 4.1% | 15.8% | 20.1% | 15.9% |
| Asset turnover | 1.55 | 1.22 | 1.05 | 0.97 | 1.10 | 1.70 | 1.60 | 1.24 | 1.20 | 1.23 | 1.06 | 0.94 | 0.91 | 1.03 | 1.17 | 1.14 | 1.05 |
| Current ratio | 2.94 | 3.30 | 3.17 | 4.18 | 2.28 | 4.31 | 4.76 | 6.72 | 4.88 | 4.34 | 3.99 | 2.74 | 3.20 | 2.84 | 3.23 | 4.10 | 4.19 |
| Debt to equity | 11.8% | 4.1% | 5.1% | 0.0% | 1.1% | 0.8% | 1.1% | 0.2% | 27.1% | 24.3% | 66.6% | 66.4% | 52.6% | 52.9% | 58.9% | 45.6% | 33.3% |
| Interest cover (operating income ÷ interest) | — | — | n/m | n/m | n/m | 21.8x | — | — | 22.7x | 29.9x | 12.9x | 11.0x | 10.8x | 12.9x | 12.9x | 16.0x | 15.4x |
| Effective tax rate | 15.9% | — | — | — | — | 2.2% | — | 37.9% | 23.8% | 22.7% | 19.0% | 19.7% | 25.0% | 19.2% | 25.5% | 24.2% | 20.7% |
| R&D as % of revenue | 7.9% | 12.0% | 14.6% | 13.7% | 12.5% | 6.0% | 5.6% | 8.4% | 6.9% | 6.6% | 11.5% | 7.1% | 6.1% | 5.9% | 5.5% | 4.3% | 4.8% |
| SG&A as % of revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 7.8% | 10.3% | 10.9% |
| Capital spending as % of revenue | 1.1% | 2.0% | 0.7% | 0.5% | 1.8% | 1.5% | 2.8% | 4.1% | 5.1% | 1.5% | 4.7% | 3.9% | — | — | 1.9% | 0.6% | 0.9% |
| Free cash flow ÷ net income | 99.7% | — | — | — | — | 18.9% | 51.7% | 134.1% | 46.7% | 72.4% | −62.4% | −54.4% | — | — | −32.6% | 49.5% | 88.9% |
| Dividends and buybacks ÷ free cash flow | — | — | — | — | — | 292.9% | 11.9% | 10.1% | 205.5% | 76.5% | — | — | — | — | — | 50.4% | — |
| Quarter | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 | 2027 Q1Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 30.2% | 33.3% | 20.0% | 29.0% | 30.8% | 30.7% | 34.8% | 33.4% |
| Operating margin | 16.0% | 20.9% | 7.7% | 16.8% | 17.5% | 15.5% | 17.3% | 17.1% |
| Net margin | 12.1% | 18.8% | 6.8% | 25.3% | 11.7% | 19.7% | 14.0% | 14.8% |
| Free-cash-flow margin | −27.9% | 3.3% | −1.5% | 11.9% | 18.8% | 7.6% | −2.3% | 29.9% |
| Current ratio | 2.58 | 2.73 | 3.23 | 3.73 | 4.03 | 3.67 | 4.10 | 4.19 |
| Debt to equity | 32.9% | 27.9% | 42.1% | 20.8% | 19.2% | 31.6% | 36.8% | 24.9% |
| R&D as % of revenue | 5.6% | 5.4% | 5.2% | 4.1% | 3.9% | 4.1% | 5.0% | 5.9% |
| SG&A as % of revenue | 8.6% | 7.0% | 7.1% | 8.0% | 9.4% | 11.1% | 12.5% | 10.4% |
Financial health
- Short-term assets cover short-term liabilities $54m of assets due within a year against $13m of liabilities due within a year.
- Short-term assets cover long-term liabilities $54m short-term assets against $14m of longer-dated liabilities.
- More cash than debt $12m of cash against $12m of debt.
- Debt below 40% of shareholders' equity Debt is 25% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 47% to 25% over five years.
- A year's operating cash flow covers at least 20% of debt $11m of operating cash flow against $12m of debt.
- Operating profit covers interest at least five times over Operating income of $13m against $872,000 of interest.
Moat
Strong moat
How hard PRO DEX's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 20 / 20
Net income has been a median 14.1% of total assets over 10 years.
- Pricing power 10 / 20
Gross margin has been a median 33.4%, moving by 3.6 percentage points (standard deviation) across 10 years.
- Durability 14 / 20
Operating margin has been a median 14.9%; its worst year was 10.9%.
- Cash conversion 6 / 20
Free cash flow was positive in 5 of 10 years, at a median 1.6% of revenue.
- Discipline 20 / 20
The diluted share count fell 18.1% over five years; stock-based pay has been a median 0.8% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Compare with peers
- Tela Bio, Inc. statistics
- Sight Sciences, Inc. statistics
- Avita Medical, Inc. statistics
- Electromed, Inc. statistics
- Pulmonx Corp statistics
Head to head: PDEX vs TELAPDEX vs SGHTPDEX vs RCELELMD vs PDEX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies